Tizaterkib AZD0364|cas:2097416-76-5|西域试剂

Tizaterkib AZD0364,99.71%

产品编号：Bellancom-111483| CAS NO：2097416-76-5| 分子式：C₂₄H₂₄F₂N₈O₂| 分子量：494.50

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-111483	￥2800.00	杭州北京（现货）
Bellancom-111483	￥4800.00	杭州北京（现货）
Bellancom-111483	￥9900.00	杭州北京（现货）
Bellancom-111483	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Tizaterkib AZD0364

产品介绍

Tizaterkib (AZD0364) 是一种有效的选择性 ERK2 抑制剂，IC₅₀ 为 0.6 nM。详细信息请参考专利文献 WO2017080979A1 中的化合物 example 18。

生物活性

Tizaterkib (AZD0364) is a potent and selective ERK2 inhibitor extracted from patent WO2017080979A1, compound example 18, has an IC₅₀ of 0.6 nM.

体外研究

Tizaterkib is measured in the ERK2 mass spectrometry and A375 phospho-p90RSK assays with IC₅₀s of 0.6 nM and 5.7 nM, respectively. Tizaterkib can inhibit the growth of a panel of cancer cell lines (A549, H2122, H2009, and Calu6 cell lines) with KRAS mutations as a monotherapy and this effect is synergistically enhanced by treatment with Selumetinib.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Tumor growth inhibition by Tizaterkib ethanesulfonic acid (Example 18a) in combination with MEK inhibitor Selumetinib is measured. Studies are performed in the A549 xenograft model. Selumetinib is dosed twice daily (BiD) 8 hours apart and Tizaterkib ethanesulfonic acid is dosed once daily (QD) 4 hours after the first Selumetinib dose. Both compounds are dosed continuously for 3 weeks. Both vehicles are dosed in the vehicle group. Both Selumetinib and Tizaterkib ethanesulfonic acid reduce tumor growth relative to vehicle only control. The combination of Selumetinib and Tizaterkib ethanesulfonic acid results in a reduction in tumor growth.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (202.22 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0222 mL	10.1112 mL	20.2224 mL
5 mM	0.4044 mL	2.0222 mL	4.0445 mL
10 mM	0.2022 mL	1.0111 mL	2.0222 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.21 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。